logo

Acasti Pharma, Inc. (ACST)



Trade ACST now with
  Date
  Headline
12/21/2017 8:56:46 AM Acasti Pharma Reports Pricing Of $10 Mln Offering Of Common Shares And Warrants
3/30/2017 8:04:57 AM Acasti Plans To Proceed With Phase 3 Development Program For CaPre, Following Recent End-of-Phase 2 Meeting With FDA
11/28/2016 8:04:55 AM Acasti Pharma Names Linda O'Keefe CFO
10/26/2016 8:08:06 AM Acasti Pharma Builds Intellectual Property Portfolio With Newly Issued U.S. Patent For CaPre
9/14/2016 8:08:18 AM Acasti Pharma Unveils Positive CaPre Omega-3 Bridging Study Data
5/30/2016 8:02:47 AM Acasti Pharma Grants 310,400 Stock Options Under Its Stock Option Plan To Its Employees At C$1.99
5/12/2016 8:09:58 AM Acasti Pharma Names Jan D'Alvise President & CEO, Effective June 1
1/7/2016 7:32:26 PM Acasti & Neptune Enter Into Transactional Arrangement & Sign Operational Agreements
12/16/2015 7:52:02 AM Acasti Pharma Receives Positive Feedback From FDA On Proposed Development Pathway For CaPre
9/29/2015 7:05:30 AM Acasti Pharma Announces 1-for-10 Reverse Stock Split
  
 
>